Login
$MLYS
$14.29 -$0.24 (1.65%) After hours

$MLYS SEC Filings

Filed On Filing
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 –

29 Oct 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

Mineralys Therapeutics, Inc. (the Company) and Tanabe Pharma Corporation (Tanabe) were previously parties to that certain License Agreement, dated July 9, 2020 and amended on November 24, 2020, June 15, 2023, May 29, 2025 and June 2, 202...

20 Oct 2026 Form 4: Peterson Kristine, Director

Received 12,400 shares as a grant or award · Granted 16,600 Stock Option

20 Oct 2026 Form 3: Peterson Kristine, Director

No securities owned

20 Oct 2026 Form 4: Coats Lonnel, Director

Received 12,400 shares as a grant or award · Granted 16,600 Stock Option

20 Oct 2026 Form 3: Coats Lonnel, Director

No securities owned

19 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 16, 2026, the Board of Directors (the Board) of Mineralys Therapeutics, Inc. (the Company) appointed Kristine Peterson and Lonnel Coats to the Board effective as of October 19, 2026, increasing the size of the Board from seven...

13 Oct 2026 144
02 Oct 2026 Form 4: Congleton Jon, Director

Sold 75,000 shares ($1.91M)

30 Sep 2026 144
24 Sep 2026 Form 4: Slingsby Brian Taylor, Director

Sold 104,320 shares ($3.01M)

22 Sep 2026 Form 4: Warren Eric, Chief Commercial Officer

Received 7,438 shares by exercise or conversion ($98.5K) · Sold 7,438 shares ($209K)

22 Sep 2026 144
21 Sep 2026 144
17 Sep 2026 Form 4: Karydas Daphne, Director

Received 3,000 shares by exercise or conversion ($36.1K) · Sold 3,000 shares ($85.7K)

17 Sep 2026 144
15 Sep 2026 144
14 Sep 2026 144
09 Sep 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support